Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating safety and efficacy of multiple dosing with VB10.NEO and bempegaldesleukin (NKTR-214) in locally advanced or metastatic solid tumours …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Tumours

Drugs mentioned

• Bempegaldesleukin (bempegaldesleukin)
• NKTR-214 (bempegaldesleukin)
• VB10.NEO (VB10.NEO)

Snippet

Sponsor: Nykode Therapeutics ASA | Conditions: Locally Advanced or Metastatic Solid Tumours | Phase 1, Phase 2 | Status: COMPLETED